[{"address1": "150 Cambridgepark Drive", "address2": "8th Floor, Suite 2", "city": "Cambridge", "state": "MA", "zip": "02140", "country": "United States", "phone": "617 221 9059", "website": "https://pyxisoncology.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Pyxis Oncology, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody, which is in Phase 1 clinical trial for the treatment of solid tumors, including non-small cell lung cancer (NSCLC) without driver mutations/translocations, breast cancer, endometrial cancer, thyroid cancer, kidney cancer, cholangiocarcinoma, bladder cancer, colorectal cancer, and head and neck squamous cell carcinoma. The company's antibody drug conjugate product candidate is PYX-201, an investigational human immunoglobulin G1 isotype site-specifically conjugated, which is in Phase 1 clinical trial for solid tumors, including NSCLC, hormone receptor-positive breast cancer, ovarian cancer, thyroid cancer, pancreatic ductal adenocarcinoma, soft tissue sarcoma, hepatocellular carcinoma, and kidney cancer. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.", "fullTimeEmployees": 67, "companyOfficers": [{"maxAge": 1, "name": "Mr. John L. Flavin M.B.A., MBA, Ph.D.", "age": 52, "title": "Co-Founder & Independent Chairman", "yearBorn": 1971, "fiscalYear": 2022, "totalPay": 87500, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Lara S. Sullivan M.D., MBA", "title": "CEO, President & Director", "fiscalYear": 2022, "totalPay": 876058, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Pamela Yanchik Connealy M.B.A.", "age": 61, "title": "CFO & COO", "yearBorn": 1962, "fiscalYear": 2022, "totalPay": 685096, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Jitendra  Wadhane", "age": 42, "title": "Chief Accounting Officer, Senior VP of Finance & Corporate Controller", "yearBorn": 1981, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Balu N. Balasubramanian Ph.D.", "title": "Interim Chief Technology Officer", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Jan  Pinkas Ph.D.", "title": "Chief Scientific Officer", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Charles T. Gombar Ph.D.", "title": "Senior Vice President of Portfolio & Program Management", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Ken  Kobayashi FACP, M.D.", "title": "Chief Medical Officer", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1672444800, "maxAge": 86400, "priceHint": 4, "previousClose": 3.16, "open": 3.15, "dayLow": 3.0, "dayHigh": 4.1, "regularMarketPreviousClose": 3.16, "regularMarketOpen": 3.15, "regularMarketDayLow": 3.0, "regularMarketDayHigh": 4.1, "beta": 1.088, "forwardPE": -2.7622378, "volume": 6869601, "regularMarketVolume": 6869601, "averageVolume": 214875, "averageVolume10days": 440150, "averageDailyVolume10Day": 440150, "bid": 3.85, "ask": 3.89, "bidSize": 1000, "askSize": 1200, "marketCap": 175075856, "fiftyTwoWeekLow": 1.35, "fiftyTwoWeekHigh": 6.92, "fiftyDayAverage": 1.9057, "twoHundredDayAverage": 2.3611, "currency": "USD", "enterpriseValue": 63653264, "floatShares": 29805323, "sharesOutstanding": 44323000, "sharesShort": 611116, "sharesShortPriorMonth": 674635, "sharesShortPreviousMonthDate": 1702598400, "dateShortInterest": 1705017600, "sharesPercentSharesOut": 0.0138, "heldPercentInsiders": 0.28897, "heldPercentInstitutions": 0.19122, "shortRatio": 2.63, "shortPercentOfFloat": 0.0166, "impliedSharesOutstanding": 44323000, "bookValue": 3.114, "priceToBook": 1.2684649, "lastFiscalYearEnd": 1672444800, "nextFiscalYearEnd": 1703980800, "mostRecentQuarter": 1696032000, "netIncomeToCommon": -94294000, "trailingEps": -2.56, "forwardEps": -1.43, "pegRatio": -0.05, "enterpriseToEbitda": -0.638, "52WeekChange": 1.025641, "SandP52WeekChange": 0.21733451, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "PYXS", "underlyingSymbol": "PYXS", "shortName": "Pyxis Oncology, Inc.", "longName": "Pyxis Oncology, Inc.", "firstTradeDateEpochUtc": 1633699800, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "52f958b2-f40f-3ac7-b706-60c2d6f7c43d", "messageBoardId": "finmb_629268721", "gmtOffSetMilliseconds": -18000000, "currentPrice": 3.95, "targetHighPrice": 12.0, "targetLowPrice": 4.0, "targetMeanPrice": 7.4, "targetMedianPrice": 7.0, "recommendationMean": 1.5, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 5, "totalCash": 132967000, "totalCashPerShare": 3.001, "ebitda": -99773000, "totalDebt": 21618000, "quickRatio": 4.693, "currentRatio": 4.909, "debtToEquity": 15.671, "returnOnAssets": -0.3081, "returnOnEquity": -0.57726, "freeCashflow": -46601248, "operatingCashflow": -72842000, "financialCurrency": "USD", "trailingPegRatio": null}]